Mirdametinib - Generic Drug Details

What are the generic drug sources for mirdametinib and what is the scope of patent protection?

Mirdametinib is the generic ingredient in one branded drug marketed by Springworks and is included in two NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mirdametinib has fifty-seven patent family members in twelve countries.

One supplier is listed for this compound.

Summary for mirdametinib

International Patents:	57
US Patents:	22
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	17
Patent Applications:	3,775
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for mirdametinib
What excipients (inactive ingredients) are in mirdametinib?	mirdametinib excipients list
DailyMed Link:	mirdametinib at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for mirdametinib

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION

Dosage:

TABLET, FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for mirdametinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
St. Justine's Hospital	PHASE1
National Cancer Institute (NCI)	PHASE2
National Cancer Institute (NCI)	PHASE1

See all mirdametinib clinical trials

Pharmacology for mirdametinib

Drug Class	Kinase Inhibitor
Mechanism of Action	Mitogen-Activated Protein Kinase Kinase 1 Inhibitors Mitogen-Activated Protein Kinase Kinase 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for mirdametinib

L01EE	Mitogen-activated protein kinase (MEK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for mirdametinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Springworks	GOMEKLI	mirdametinib	CAPSULE;ORAL	219389-002	Feb 11, 2025		RX	Yes	Yes
Springworks	GOMEKLI	mirdametinib	CAPSULE;ORAL	219389-001	Feb 11, 2025		RX	Yes	No			Y
Springworks	GOMEKLI	mirdametinib	TABLET, FOR SUSPENSION;ORAL	219379-001	Feb 11, 2025		RX	Yes	Yes
Springworks	GOMEKLI	mirdametinib	TABLET, FOR SUSPENSION;ORAL	219379-001	Feb 11, 2025		RX	Yes	Yes
Springworks	GOMEKLI	mirdametinib	TABLET, FOR SUSPENSION;ORAL	219379-001	Feb 11, 2025		RX	Yes	Yes

International Patents for mirdametinib

Country	Patent Number	Title	Estimated Expiration
Mexico	2025010770
China	118973559
European Patent Office	4680218
Peru	20242178	DOSIFICACION NO LINEAL DE MIRDAMETINIB
Mexico	2024011249	DOSIFICACION NO LINEAL DE MIRDAMETINIB. (NON-LINEAR DOSING OF MIRDAMETINIB.)

Mirdametinib Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Mirdametinib?

Mirdametinib is a MEK inhibitor developed primarily for treating tumors driven by MAPK pathway alterations. The drug has advanced through clinical trials targeting conditions including melanoma, non-small cell lung cancer (NSCLC), and other solid tumors. Its market prospects depend on several factors:

Competitive Landscape

• Key Competitors: Drugs such as trametinib (GlaxoSmithKline), binimetinib (Pfizer), and cobimetinib (Genentech) dominate the MEK inhibitor segment.
• Unique Positioning: Mirdametinib faces competition from established therapies; however, its potential efficacy in niche indications and combination therapies offers growth opportunities.
• Clinical Stage: Currently in Phase II or III trials for specific indications, with regulatory submissions possibly pending.

Regulatory Status

• Approvals: None at this time; clinical trial results influence future approvals.
• Path to Market: Regulatory agencies prioritize safety and efficacy data; positive trial outcomes can lead to accelerated review pathways, especially for rare or unmet needs.

Market Drivers

• Unmet Medical Need: Significant for melanoma resistant to BRAF inhibitors.
• Biomarker-Driven Therapy: Increased adoption of genomic screening enhances market access.
• Combination regimens: Combining mirdametinib with other targeted therapies or immunotherapies can expand its indications.

Market Restraints

• Toxicity Profile: MEK inhibitors often cause rash, cardiomyopathy, ocular toxicities, which can limit dosage or patient eligibility.
• Efficacy Concerns: Resistance mechanisms can diminish long-term effectiveness.
• Pricing and Reimbursement: High development costs and price ceilings in different markets.

Estimated Market Size

• The global MEK inhibitor market was valued at approximately $2.5 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8-10% through 2030 [1].
• Mirdametinib’s share depends on trial success and regulatory approval, with niche markets in rare melanoma or specific mutations offering smaller revenue segments initially.

What Is the Financial Trajectory for Mirdametinib?

Current Investment and Expenses

• Development costs for anticancer drugs average $1.3 billion, with MEK inhibitors typically constituting a substantial portion [2].
• Clinical trials for mirdametinib involve multiple phases, with ongoing expenditures in Phase II and III.

Revenue Potential

• Upon approval, price points for MEK inhibitors range from $10,000 to $15,000 monthly per patient, varying by indication and region.
• Estimated peak sales could reach $300 million to $1 billion annually, contingent on approval breadth, market penetration, and competitor dynamics [3].

Timeframe to Revenue Generation

• Drug development phases: typically 8-12 years from research to market.
• Mirdametinib likely follows a 2023-2030 timeline, assuming successful trial outcomes expedite approval.
• Post-approval, sales ramp up over 1-3 years as formulated markets adopt the drug.

Risks Impacting Financial Trajectory

• Regulatory Delays: Can postpone revenue.
• Market Penetration: Slow adoption may limit revenues initially.
• Patent Life and Market Exclusivity: Usually 10-12 years in key markets; expiration can open generic competition.

Investment Considerations

• Investors should monitor trial results, regulatory feedback, and competitive responses.
• Cost controls in clinical phases influence overall profitability.

Summary of Market and Financial Outlook

Parameter	Estimates	Notes
Market size (2022)	~$2.5 billion	Global MEK inhibitor market
CAGR (2023-2030)	8-10%	Driven by emerging indications
Peak sales (per indication)	$300 million - $1 billion	Contingent on approval and market penetration
Development timeline	8-12 years	From discovery through approval
Revenue start date	2024-2027 (assuming approval in 2023–2024)	Post-approval ramp-up

Key Takeaways

• Mirdametinib faces substantial competition within the MEK inhibitor market but has potential in niche indications, especially where biomarker-driven therapies show promise.
• The regulatory pathway hinges on successful trial outcomes, with market exclusivity limited to approximately a decade post-approval.
• The financial prospects depend on clinical success, approval timing, and market access strategies, with peak revenues potentially reaching into hundreds of millions annually.

FAQs

1. How does mirdametinib compare to other MEK inhibitors?
Mirdametinib is in clinical development, with limited published efficacy and safety data compared to established agents like trametinib, which has global approval and established indications.

2. What are the primary challenges in bringing mirdametinib to market?
Key challenges include demonstrating sufficient efficacy in clinical trials, managing toxicity profiles, and navigating regulatory approval processes amid competition.

3. Which indications offer the highest revenue potential for mirdametinib?
Melanoma with BRAF or NRAS mutations and certain lung cancers with MAPK pathway alterations provide the most immediate opportunities.

4. How long does it typically take for a drug like mirdametinib to reach peak sales?
Approximately 8-10 years from early clinical trials, assuming swift development progress and regulatory approval.

5. What factors could accelerate or delay the drug’s market entry?
Accelerators include positive trial results and expedited review pathways; delays stem from safety issues, regulatory objections, or strategic business decisions.

---

References:

1. Valuates Reports. "Global MEK Inhibitors Market Size, Share & Trends Analysis Report." 2022.
2. DiMasi, J. A., et al. "Innovation in the pharmaceutical industry: New estimates of R&D costs." Journal of Health Economics. 2016.
3. EvaluatePharma. "World Preview 2022."